<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Hepatitis B - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    

    
    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Hepatitis B</span>
        </nav>

        <header class="page-header">
            <h1>Hepatitis B</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Infectious Disease</span>
                
                
                <span class="badge badge-mondo">
                    <a href="https://monarchinitiative.org/disease/MONDO:0005344" target="_blank">
                        MONDO:0005344
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Viral Infection</span>
                
            </div>
        </header>

        <!-- Stats bar -->
        <div class="stats-bar">
            <div class="stat-item">
                <div class="stat-value">6</div>
                <div class="stat-label">Mechanisms</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">10</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Genes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Treatments</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Subtypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
        </div>

        <!-- Subtypes -->
        

        <!-- Pathophysiology -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">⚙</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">6</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Hepatocyte Infection and cccDNA Formation</div>
                
                <div class="item-desc">HBV enters hepatocytes via NTCP receptor binding, and viral rcDNA is converted to covalently closed circular DNA (cccDNA) which forms a stable chromatinized minichromosome in the nucleus, enabling persistent infection.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Hepatocyte
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000182" target="_blank" style="color: inherit; margin-left: 4px;">↗</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">viral entry into host cell</span>
                    
                    <span class="tag tag-bio">epigenetic regulation of gene expression</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/33573130" target="_blank">PMID:33573130</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Human hepatitis B virus (HBV) can cause chronic, lifelong infection of the liver that may lead to persistent or episodic immune-mediated inflammation against virus-infected hepatocytes."</div>
                
                
                <div class="evidence-explanation">This reference confirms that HBV infects hepatocytes and leads to chronic inflammation.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/32866519" target="_blank">PMID:32866519</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"&#39;Hepatitis B virus (HBV) specifically infects hepatocytes and causes severe liver diseases."</div>
                
                
                <div class="evidence-explanation">This reference confirms that HBV specifically infects hepatocytes.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/30518652" target="_blank">PMID:30518652</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Distinct populations of hepatocytes infected with hepatitis B virus (HBV) or only harboring HBV DNA integrations coexist within an HBV chronically infected liver."</div>
                
                
                <div class="evidence-explanation">This reference confirms that HBV integrates into the host genome within hepatocytes and persists.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">HBV DNA Integration</div>
                
                <div class="item-desc">Integration of viral dslDNA into host genome occurs at sites of DNA damage, driving insertional mutagenesis, structural rearrangements, and activation of proto-oncogenes.</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">DNA integration</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Chronic Inflammation</div>
                
                <div class="item-desc">Persistent immune response against HBV-infected hepatocytes leads to liver damage mediated by T cells, NK cells, and Kupffer cells.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        CD8-positive, alpha-beta T cell
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000625" target="_blank" style="color: inherit; margin-left: 4px;">↗</a>
                        
                    </span>
                    
                    <span class="tag tag-cell">
                        natural killer cell
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000623" target="_blank" style="color: inherit; margin-left: 4px;">↗</a>
                        
                    </span>
                    
                    <span class="tag tag-cell">
                        inflammatory macrophage
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000863" target="_blank" style="color: inherit; margin-left: 4px;">↗</a>
                        
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/8571172" target="_blank">PMID:8571172</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The immune response to HBV-encoded antigens is responsible both for viral clearance and for disease pathogenesis during this infection."</div>
                
                
                <div class="evidence-explanation">This reference supports that the immune response against HBV-infected hepatocytes contributes to liver damage, which aligns with the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/34543610" target="_blank">PMID:34543610</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Cirrhosis is widely prevalent worldwide and can be a consequence of different causes, such as... hepatitis B or C infection."</div>
                
                
                <div class="evidence-explanation">This reference supports the link between chronic HBV infection and cirrhosis, which is a downstream effect of persistent immune response and liver damage.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/32147592" target="_blank">PMID:32147592</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Progression of liver fibrosis still occurs in some patients with chronic hepatitis B virus (HBV) infection despite antiviral therapy."</div>
                
                
                <div class="evidence-explanation">This reference supports that chronic HBV infection leads to liver fibrosis, which is a downstream effect of immune response and liver damage.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Immune Evasion and T Cell Exhaustion</div>
                
                <div class="item-desc">HBV evades innate immune detection through dampened TLR, cGAS-STING, and RIG-I-MAVS pathways. Chronic infection leads to T cell exhaustion with upregulation of PD-1, CTLA-4, and TIM-3 checkpoint receptors.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        CD8-positive, alpha-beta T cell
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000625" target="_blank" style="color: inherit; margin-left: 4px;">↗</a>
                        
                    </span>
                    
                    <span class="tag tag-cell">
                        regulatory T cell
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000815" target="_blank" style="color: inherit; margin-left: 4px;">↗</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">negative regulation of T cell activation</span>
                    
                    <span class="tag tag-bio">cGAS-STING signaling pathway</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/16461223" target="_blank">PMID:16461223</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"The immune system plays an important role in determining the outcome of hepatitis B virus (HBV) infection... Multispecific antiviral CD4 and CD8 responses with a type 1 cytokine production can be observed in patients who recover from acute HBV infection."</div>
                
                
                <div class="evidence-explanation">The reference supports the role of T cells in immune clearance but does not mention B cells.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/36936922" target="_blank">PMID:36936922</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"The clearance of HBV with virus-specific CD8 T cells is critical for a functional cure."</div>
                
                
                <div class="evidence-explanation">The reference supports the role of T cells in immune clearance but does not mention B cells.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Liver Fibrosis</div>
                
                <div class="item-desc">Chronic inflammation promotes fibrotic tissue deposition replacing healthy liver cells.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/17613356" target="_blank">PMID:17613356</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Liver fibrosis results from chronic damage to the liver in conjunction with the progressive accumulation of fibrillar extracellular matrix proteins."</div>
                
                
                <div class="evidence-explanation">The statement is supported as liver fibrosis involves the replacement of healthy liver cells with fibrotic tissue due to chronic inflammation.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/33528280" target="_blank">PMID:33528280</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Chronic inflammation involves CCL11 and IL-13 to facilitate the development of liver cirrhosis and fibrosis in chronic hepatitis B virus infection."</div>
                
                
                <div class="evidence-explanation">The statement is supported as chronic inflammation promotes liver fibrosis through specific inflammatory pathways.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/26691189" target="_blank">PMID:26691189</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Chronic unresolved inflammation is associated with persistent hepatic injury and concurrent regeneration, leading to sequential development of fibrosis, cirrhosis, and eventually HCC."</div>
                
                
                <div class="evidence-explanation">The statement is supported as chronic inflammation leads to liver fibrosis and cirrhosis.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Cirrhosis</div>
                
                <div class="item-desc">Extensive fibrosis and scarring significantly impair liver function.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/17981234" target="_blank">PMID:17981234</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Untreated, chronic hepatitis B acquired early in life results in cirrhosis, liver failure, or hepatocellular carcinoma in up to 40% of individuals."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement by indicating that chronic hepatitis B can lead to cirrhosis, which is associated with extensive fibrosis and scarring that impair liver function.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/19577114" target="_blank">PMID:19577114</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Cirrhosis is defined histologically as an advanced form of progressive hepatic fibrosis with distortion of the hepatic architecture and regenerative nodule formation."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement by describing cirrhosis as an advanced form of hepatic fibrosis that distorts liver architecture, thereby impairing liver function.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/17613356" target="_blank">PMID:17613356</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Liver fibrosis results from chronic damage to the liver in conjunction with the progressive accumulation of fibrillar extracellular matrix proteins."</div>
                
                
                <div class="evidence-explanation">While this reference discusses liver fibrosis resulting from chronic liver damage, it does not explicitly connect it to cirrhosis or the impairment of liver function.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">⬡</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="graph-warning">
                <strong>Referential integrity issues (1):</strong>
                <ul>
                    
                    <li>Target &#39;Hepatocellular Carcinoma&#39; (from &#39;HBV DNA Integration&#39;) not found in named elements</li>
                    
                    
                </ul>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph TD
    Hepatocyte_Infection_and_cccDNA_Formation[&#34;Hepatocyte Infection and cccDNA Formation&#34;]
    Chronic_Inflammation[&#34;Chronic Inflammation&#34;]
    Hepatocellular_Carcinoma[&#34;Hepatocellular Carcinoma&#34;]
    HBV_DNA_Integration[&#34;HBV DNA Integration&#34;]
    Liver_Fibrosis[&#34;Liver Fibrosis&#34;]
    Cirrhosis[&#34;Cirrhosis&#34;]

    Hepatocyte_Infection_and_cccDNA_Formation --&gt; Chronic_Inflammation
    Hepatocyte_Infection_and_cccDNA_Formation --&gt; HBV_DNA_Integration
    HBV_DNA_Integration -.-&gt; Hepatocellular_Carcinoma
    Chronic_Inflammation --&gt; Liver_Fibrosis
    Chronic_Inflammation --&gt; Cirrhosis
    Liver_Fibrosis --&gt; Cirrhosis

    style Hepatocyte_Infection_and_cccDNA_Formation fill:#dbeafe
    style Chronic_Inflammation fill:#dbeafe
    style Hepatocellular_Carcinoma fill:#fee2e2,stroke:#dc2626,stroke-dasharray: 5 5
    style HBV_DNA_Integration fill:#dbeafe
    style Liver_Fibrosis fill:#dbeafe
    style Cirrhosis fill:#dbeafe</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">●</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">10</span>
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Jaundice
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Gastrointestinal</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0000952" target="_blank">
                            HP:0000952
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Due to liver dysfunction causing elevated bilirubin levels</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/24266913" target="_blank">PMID:24266913</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Chronically infected patients should be followed on a regular basis, preferably every 6 months, with liver function tests, and when appropriate, HBV DNA levels. Those who meet the criteria for high risk for HCC should undergo liver ultrasound every 6 months. Powerful antiviral medications are..."</div>
                
                
                <div class="evidence-explanation">The literature mentions the management of chronic Hepatitis B and its effects on liver function, which can lead to jaundice.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/3050928" target="_blank">PMID:3050928</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The classic presenting symptoms of viral hepatitis are jaundice, nausea, vomiting, malaise, anorexia, and dull right upper quadrant pain."</div>
                
                
                <div class="evidence-explanation">The literature explicitly lists jaundice as a classic presenting symptom of viral hepatitis, including Hepatitis B.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/34835022" target="_blank">PMID:34835022</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Hepatitis B virus (HBV) infection is one of the serious health problems in the world as HBV causes severe liver diseases."</div>
                
                
                <div class="evidence-explanation">The literature discusses the severe liver diseases caused by Hepatitis B, which can lead to jaundice due to liver dysfunction.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Fatigue
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Systemic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0012378" target="_blank">
                            HP:0012378
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/7493307" target="_blank">PMID:7493307</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Hepatitis cases scored significantly higher fatigue scores, GHQ-12 scores and muscle pain scores."</div>
                
                
                <div class="evidence-explanation">The study indicates that fatigue is more common after recovery in patients hospitalized for hepatitis B up to 30 months post-infection compared with matched controls hospitalized for other infectious diseases.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Abdominal Pain
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Gastrointestinal</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0002027" target="_blank">
                            HP:0002027
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">May be related to liver inflammation</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/24954675" target="_blank">PMID:24954675</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Hepatitis B virus is not cytopathic; both liver damage and viral control--and therefore clinical outcome--depend on the complex interplay between virus replication and host immune response."</div>
                
                
                <div class="evidence-explanation">The literature mentions liver damage and clinical outcomes related to Hepatitis B, which can include gastrointestinal symptoms like abdominal pain due to liver inflammation.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/3050928" target="_blank">PMID:3050928</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The classic presenting symptoms of viral hepatitis are jaundice, nausea, vomiting, malaise, anorexia, and dull right upper quadrant pain."</div>
                
                
                <div class="evidence-explanation">The literature lists dull right upper quadrant pain as a classic symptom of viral hepatitis, which includes Hepatitis B, supporting the statement that abdominal pain is an occasional gastrointestinal symptom related to liver inflammation.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Elevated Liver Enzymes
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Hepatic</span>
                    
                    
                </div>
                
                <div class="item-desc">Reflects liver cell damage and is a key diagnostic feature</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/34835022" target="_blank">PMID:34835022</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The HBV surface antigen (HBsAg)-positive group had a more frequent prevalence of patients with higher transaminase elevations than the HBsAg-negative group."</div>
                
                
                <div class="evidence-explanation">The study indicates that elevated liver enzymes, which reflect liver cell damage, are more frequently observed in patients with Hepatitis B virus infection.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/30418344" target="_blank">PMID:30418344</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Abnormal liver enzymes are frequently encountered in primary care offices and hospitals and may be caused by a wide variety of conditions, from mild and nonspecific to well-defined and life-threatening."</div>
                
                
                <div class="evidence-explanation">Elevated liver enzymes are a common diagnostic feature in various liver diseases, including Hepatitis B.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/29551632" target="_blank">PMID:29551632</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The prevalence of hepatitis B surface antigen (HBsAg) was 18.5% (126/680) and of liver cirrhosis was 9.4% (64/680)."</div>
                
                
                <div class="evidence-explanation">The presence of elevated liver enzymes is associated with Hepatitis B infection, as indicated by the prevalence of HBsAg in patients.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Nausea
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Gastrointestinal</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0002018" target="_blank">
                            HP:0002018
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/3050928" target="_blank">PMID:3050928</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The classic presenting symptoms of viral hepatitis are jaundice, nausea, vomiting, malaise, anorexia, and dull right upper quadrant pain."</div>
                
                
                <div class="evidence-explanation">The literature explicitly mentions nausea as a classic presenting symptom of viral hepatitis, which includes Hepatitis B.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Vomiting
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Gastrointestinal</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0002013" target="_blank">
                            HP:0002013
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/3050928" target="_blank">PMID:3050928</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"The classic presenting symptoms of viral hepatitis are jaundice, nausea, vomiting, malaise, anorexia, and dull right upper quadrant pain."</div>
                
                
                <div class="evidence-explanation">The reference mentions vomiting as one of the classic presenting symptoms of viral hepatitis, which includes Hepatitis B. However, it does not specify the frequency, so it partially supports the statement.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Fever
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Systemic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0001945" target="_blank">
                            HP:0001945
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/28223176" target="_blank">PMID:28223176</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Prodromal fever indicated more severe liver injury and was independently associated with hepatitis B e antigen (HBeAg) negativity."</div>
                
                
                <div class="evidence-explanation">The study indicates that fever can be associated with acute hepatitis B, particularly in severe cases, but it does not explicitly categorize fever as an occasional systemic manifestation.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/34913875" target="_blank">PMID:34913875</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Several of these extrahepatic syndromes have been well described, including systemic vasculitides, glomerulonephritis, and cutaneous manifestations."</div>
                
                
                <div class="evidence-explanation">While the reference mentions systemic manifestations of hepatitis B, it does not specifically mention fever as one of them.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/35499229" target="_blank">PMID:35499229</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"The study confirms the endemicity of hepatitis B and enteric fever in the area."</div>
                
                
                <div class="evidence-explanation">The study mentions the prevalence of hepatitis B among febrile patients but does not specifically categorize fever as an occasional systemic manifestation of hepatitis B.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Hepatomegaly
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Hepatic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0002240" target="_blank">
                            HP:0002240
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Liver enlargement</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/12150847" target="_blank">PMID:12150847</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Occult hepatitis B occurs in a number of clinical settings."</div>
                
                
                <div class="evidence-explanation">While the abstract does not specifically mention hepatomegaly as a frequent symptom, it implies that various liver-related conditions are associated with hepatitis B, supporting the occasional occurrence of hepatomegaly.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/19682192" target="_blank">PMID:19682192</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Severe acute exacerbation is a unique presentation of chronic hepatitis B characterized by very high alanine aminotransferase level accompanied by jaundice and hepatic decompensation."</div>
                
                
                <div class="evidence-explanation">The text describes severe liver conditions related to chronic hepatitis B, but does not directly mention hepatomegaly. It suggests severe liver involvement, which could include hepatomegaly.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Arthralgias
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Systemic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0002829" target="_blank">
                            HP:0002829
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Joint pain</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/18760074" target="_blank">PMID:18760074</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The most commonly described include skin rash, arthritis, arthralgia, glomerulonephritis, polyarteritis nodosa, and papular acrodermatitis etc."</div>
                
                
                <div class="evidence-explanation">The reference confirms that arthralgia (joint pain) is a commonly described extrahepatic manifestation of Hepatitis B.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Rash
                    
                    <span class="phenotype-freq">OCCASIONAL</span>
                    
                    
                    <span class="phenotype-category">Dermatologic</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0000988" target="_blank">
                            HP:0000988
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/6133886" target="_blank">PMID:6133886</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Dermatologic manifestations of hepatitis B virus infection."</div>
                
                
                <div class="evidence-explanation">The title of the reference directly indicates the presence of dermatologic manifestations, supporting the statement that hepatitis B can cause occasional dermatologic conditions like rash.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/1185334" target="_blank">PMID:1185334</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The association of arthritis, arthralgia, and various types of skin rashes, as a prodrome to viral hepatitis, although well recognized in adults, has not been well described in children."</div>
                
                
                <div class="evidence-explanation">The reference mentions that skin rashes are recognized as prodromal manifestations of viral hepatitis, including hepatitis B, supporting the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/1532114" target="_blank">PMID:1532114</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The most frequent adverse reactions were myalgia/arthralgia lasting longer than 3 days (14), followed by skin rashes (eight) and dizziness (seven)."</div>
                
                
                <div class="evidence-explanation">The reference notes that skin rashes were among the most frequent adverse reactions to the hepatitis B vaccine, indicating that hepatitis B can be associated with dermatologic manifestations like rash.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">🧬</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    HBV Genotype
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/19072424" target="_blank">PMID:19072424</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"There are eight different genotypes named A-H. Genotypes have distinct geographic distribution in different regions of the world. There exists a difference in the disease profile between different genotypes."</div>
                
                
                <div class="evidence-explanation">The reference supports the presence of multiple HBV genotypes (A-H) and indicates that these genotypes influence disease progression and treatment response.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/26255971" target="_blank">PMID:26255971</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The clinical course of hepatitis B virus (HBV) infection greatly differs in individuals. Various viral, host, and environmental factors influence the natural history of HBV infection."</div>
                
                
                <div class="evidence-explanation">The reference supports the influence of various factors, including viral genotypes, on the clinical course of HBV infection.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/34593148" target="_blank">PMID:34593148</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Various HBV genotypes and their impact on the clinical course are discussed. The relationship of HBV serologies and HBV DNA to disease progression is outlined."</div>
                
                
                <div class="evidence-explanation">The reference supports the statement that different HBV genotypes influence disease progression and treatment response.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">💊</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Antiviral Medications
                    
                    <span class="phenotype-id">
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/maxo/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FMAXO_0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Includes drugs like tenofovir and entecavir to suppress HBV replication.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/26732483" target="_blank">PMID:26732483</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have been recommended as the first-line anti-HBV drugs for excellent viral suppression with a low risk of antiviral resistance."</div>
                
                
                <div class="evidence-explanation">The reference explicitly mentions tenofovir and entecavir as first-line drugs for suppressing HBV replication.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/26054819" target="_blank">PMID:26054819</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Since 2008, it has also been indicated for treatment of chronic HBV infection or HIV/HBV co-infection. The aim of the treatment consists in suppressing viral replication, thus reducing hepatic complications and improving patient survival."</div>
                
                
                <div class="evidence-explanation">The reference supports the use of tenofovir for suppressing HBV replication.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/32050881" target="_blank">PMID:32050881</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The aim of this study was to evaluate the histological, virological, serological and biochemical response rates in CHB patients receiving tenofovir or entecavir therapy."</div>
                
                
                <div class="evidence-explanation">The study evaluates the effects of tenofovir and entecavir in CHB patients, supporting their role in HBV suppression.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Interferon Therapy
                    
                    <span class="phenotype-id">
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/maxo/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FMAXO_0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Boosts the immune system to fight the virus.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/25034484" target="_blank">PMID:25034484</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Interferon-alpha (IFN-alpha) therapy can convert CHB into inactive hepatitis B virus (HBV) infection in 20-30% of the treated patients...IFN-alpha has multiple antiviral, antiproliferative, and immunomodulatory activities."</div>
                
                
                <div class="evidence-explanation">The literature indicates that Interferon-alpha has immunomodulatory activities, which can help in controlling HBV infection, but it does not explicitly state that it &#39;boosts&#39; the immune system in the general sense.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/16461223" target="_blank">PMID:16461223</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Therapeutic strategies aimed at correcting this defective T cell reactivity could represent a complementary approach to the cure of chronic HBV infection."</div>
                
                
                <div class="evidence-explanation">The literature suggests that targeting immune responses is a strategy in treating HBV, but it does not explicitly state that Interferon Therapy &#39;boosts&#39; the immune system.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/10804945" target="_blank">PMID:10804945</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"We found IFN to be a safe and adequate mode of treatment in children with chronic HBV infection, regardless of their liver histology and transaminase levels."</div>
                
                
                <div class="evidence-explanation">The study indicates that Interferon Therapy is effective in treating HBV in children, but it does not explicitly state that it &#39;boosts&#39; the immune system.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Liver Transplant
                    
                    <span class="phenotype-id">
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/maxo/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FMAXO_0010039" target="_blank">
                            MAXO:0010039
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">For end-stage liver disease.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/29125261" target="_blank">PMID:29125261</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Liver transplantation (LT) is the only effective treatment for hepatitis B-virus (HBV) related end stage liver disease..."</div>
                
                
                <div class="evidence-explanation">This reference explicitly states that liver transplantation is the only effective treatment for end-stage liver disease caused by hepatitis B.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/17981234" target="_blank">PMID:17981234</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Until recently, the options for a patient who had end-stage hepatitis B cirrhosis were severely limited, but during the past 15 years great strides have been made in prevention and treatment of hepatitis B cirrhosis."</div>
                
                
                <div class="evidence-explanation">The reference discusses the advancements in treatment options for end-stage hepatitis B cirrhosis, implying liver transplantation as a viable option.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Regular Monitoring
                    
                </div>
                
                <div class="item-desc">Monitoring liver function and viral load to manage chronic infection.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (6 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/24266913" target="_blank">PMID:24266913</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Chronically infected patients should be followed on a regular basis, preferably every 6 months, with liver function tests, and when appropriate, HBV DNA levels."</div>
                
                
                <div class="evidence-explanation">The literature supports regular monitoring of liver function and viral load in patients with chronic hepatitis B infection.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/12776281" target="_blank">PMID:12776281</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Periodic testing for HBV DNA to assess the virological status of HBsAg-positive dialysis patients is recommended."</div>
                
                
                <div class="evidence-explanation">The study recommends regular monitoring of viral load in hepatitis B patients, supporting the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/33467927" target="_blank">PMID:33467927</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"This manuscript summarized traditional biomarkers of different hepatitis B stages and recent-developed POCT platforms (including microfluidic platforms and lateral-flow strips) and discuss the challenges associated with their use."</div>
                
                
                <div class="evidence-explanation">The article discusses the importance of monitoring hepatitis B using various biomarkers, which aligns with the statement.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 3 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Vaccination
                    
                    <span class="phenotype-id">
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/maxo/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FMAXO_0001017" target="_blank">
                            MAXO:0001017
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Hepatitis B vaccine provides prevention for uninfected individuals.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/10776195" target="_blank">PMID:10776195</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Immunization of all newborn infants and adolescents for HBV is a vital step toward eradicating HBV from the general population."</div>
                
                
                <div class="evidence-explanation">The article supports the statement by emphasizing the importance of immunizing infants and adolescents to prevent HBV infection.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/33200362" target="_blank">PMID:33200362</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Primary prevention by HBV vaccination targeting the general population starting from birth dose."</div>
                
                
                <div class="evidence-explanation">The article confirms that HBV vaccination is a primary prevention strategy for the general population.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/17298912" target="_blank">PMID:17298912</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Hepatitis B vaccines have been licensed since 1982... Long-term protection has been demonstrated."</div>
                
                
                <div class="evidence-explanation">The article discusses the long-term protection conferred by hepatitis B vaccines, supporting their role in preventing HBV infection.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ccfbf1; color: #0d9488;">🌍</div>
                <h2 class="card-title">Environmental Factors</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Poor Sterile Practices</div>
                
                <div class="item-desc">Increases the risk of transmission via medical procedures</div>
                
                
                <div class="item-desc">Inadequate infection control in healthcare settings increases HBV transmission through contaminated needles, surgical instruments, and blood products.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/20123446" target="_blank">PMID:20123446</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Increasing recognition of outbreaks involving patient-to-patient spread of hepatitis B and hepatitis C virus infections, however, has uncovered a disturbing trend. This article highlights the importance of basic infection control and the need for increased awareness of safe injection practices."</div>
                
                
                <div class="evidence-explanation">The article indicates that poor sterile practices can lead to patient-to-patient spread of hepatitis B, supporting the statement that poor sterile practices increase the risk of transmission via medical procedures.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/10840606" target="_blank">PMID:10840606</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Cases with the highest number of transmissions (one anesthesiologist with 217 HC transmissions, and one EEG technologist with 75 HB transmissions) were attributed to poor infection control practices."</div>
                
                
                <div class="evidence-explanation">The report documents numerous cases of hepatitis B transmission attributed to poor infection control practices, supporting the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/23074317" target="_blank">PMID:23074317</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"We documented HBV transmission during orthopedic surgery to 2 patients from a surgeon with HBV. This investigation highlights the importance of evaluating individuals who do not respond to 2 series of HBV vaccination, the increased risk of HBV transmission from providers with high viral loads,..."</div>
                
                
                <div class="evidence-explanation">The study demonstrates that poor sterile practices and high viral loads in healthcare providers can lead to the transmission of hepatitis B during medical procedures.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">High-risk Behaviors</div>
                
                <div class="item-desc">Includes unprotected sexual contact and intravenous drug use</div>
                
                
                <div class="item-desc">Behavioral risk factors including unprotected sexual intercourse, intravenous drug use with shared needles, and occupational exposure to blood.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/2183516" target="_blank">PMID:2183516</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"In the Western world most cases of hepatitis B virus (HBV) infection are acquired through sexual intercourse and through needle sharing by intravenous drug users (IVDU)."</div>
                
                
                <div class="evidence-explanation">The literature explicitly mentions that HBV infection is commonly acquired through sexual intercourse and needle sharing, which aligns with the statement&#39;s mention of unprotected sexual contact and intravenous drug use as high-risk behaviors.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/20411413" target="_blank">PMID:20411413</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Sex with multiple partners, sex under the influence of alcohol or drugs, and unprotected sex were the most prevalent HIV risk behaviors."</div>
                
                
                <div class="evidence-explanation">Although this reference primarily discusses HIV, it also notes that unprotected sex is a prevalent risk behavior, which supports the statement regarding high-risk behaviors for HBV.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/32338365" target="_blank">PMID:32338365</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"People who inject drugs (PWIDs) are prone to a number of blood-borne viral infections. Hepatitis B virus (HBV) and hepatitis C virus (HCV) constitute an important public health concern in this high risk group."</div>
                
                
                <div class="evidence-explanation">The literature states that people who inject drugs are at high risk for HBV, supporting the statement that intravenous drug use is a high-risk behavior for HBV.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">🔬</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Hepatitis B Surface Antigen (HBsAg)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Positive)</span>
                    
                </div>
                
                <div class="item-desc">Context: Indicates active infection</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/49464" target="_blank">PMID:49464</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"HBsAg in an individual indicates that he harbors the virus of hepatitis B; it may be present in the absence of liver disease or be found in association with both acute and chronic type B hepatitis."</div>
                
                
                <div class="evidence-explanation">The presence of HBsAg indicates that the individual harbors the hepatitis B virus, which supports the statement that a positive HBsAg indicates an active infection.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/22300111" target="_blank">PMID:22300111</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"To analyze the epidemiological, clinical, and virological characteristics of patients newly diagnosed with active hepatitis B virus (HBV) infection based on the presence of positive hepatitis B surface antigen (HBsAg)..."</div>
                
                
                <div class="evidence-explanation">The study focuses on patients newly diagnosed with active HBV infection based on the presence of positive HBsAg, supporting the statement that a positive HBsAg indicates an active infection.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/21692954" target="_blank">PMID:21692954</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Serum hepatitis B surface antigen (HBsAg) levels reflect intrahepatic hepatitis B virus (HBV) covalently closed circular DNA and may be a valuable addition to HBV DNA in the management of patients with chronic hepatitis B (CHB)."</div>
                
                
                <div class="evidence-explanation">The presence of HBsAg reflects the presence of hepatitis B virus, indicating active infection, which supports the statement.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Hepatitis B e Antigen (HBeAg)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Positive)</span>
                    
                </div>
                
                <div class="item-desc">Context: Indicates active viral replication and high infectivity</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/12124405" target="_blank">PMID:12124405</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The presence of hepatitis B e antigen (HBeAg) in serum indicates active viral replication in hepatocytes."</div>
                
                
                <div class="evidence-explanation">The study confirms that HBeAg is a surrogate marker for active hepatitis B virus replication.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/21205143" target="_blank">PMID:21205143</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"HBeAg seropositivity is a marker for active viral replication."</div>
                
                
                <div class="evidence-explanation">The article states that HBeAg is associated with highly replicative activity of the hepatitis B virus.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/7038074" target="_blank">PMID:7038074</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Hepatitis B virus markers were studied in serum and liver of 24 children with chronic hepatitis. All patients had evidence of active virus replication... Furthermore, 19 of 24 patients had hepatitis B e antigen in serum."</div>
                
                
                <div class="evidence-explanation">The study shows that the presence of HBeAg in serum is associated with active hepatitis B virus replication.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    HBV DNA
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Positive)</span>
                    
                </div>
                
                <div class="item-desc">Context: Indicates viral load and active replication</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (9 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/7030903" target="_blank">PMID:7030903</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The assay for serum HBV DNA appears to be an excellent noninvasive method for detecting active replication of HBV in HBsAg carriers."</div>
                
                
                <div class="evidence-explanation">The presence of HBV DNA in the serum is associated with active replication of HBV in the liver.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/31741331" target="_blank">PMID:31741331</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Hepatitis B virus (HBV) is a DNA virus, belonging to the Hepadnaviridae family."</div>
                
                
                <div class="evidence-explanation">The presence of HBV DNA indicates the presence of the virus and hence active replication.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/27032097" target="_blank">PMID:27032097</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Quantitative real-time PCR and HBV sequencing were performed in HBsAg-positive patients."</div>
                
                
                <div class="evidence-explanation">The presence of HBV DNA in serum is used to quantify viral load, indicating active replication.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 6 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">category: Infectious Disease
name: Hepatitis B
description: Hepatitis B is a viral infection caused by Hepatitis B Virus (HBV) that
  primarily affects the liver. It can cause both acute and chronic disease, with chronic
  infection leading to cirrhosis, liver failure, and hepatocellular carcinoma. Transmission
  occurs through blood, sexual contact, and from mother to child during birth.
parents:
- Viral Infection
infectious_agent:
- name: Hepatitis B Virus (HBV)
  description: A partially double-stranded DNA virus that infects hepatocytes via the NTCP receptor and establishes persistent cccDNA in the nucleus. HBx protein serves as a multifunctional regulator of viral transcription and host epigenetics.
  evidence:
  - reference: PMID:19399811
    supports: SUPPORT
    snippet: Hepatitis B virus (HBV) infects more than 300 million people worldwide
      and is a common cause of liver disease and liver cancer. HBV, a member of the
      Hepadnaviridae family, is a small DNA virus with unusual features similar to
      retroviruses.
    explanation: The provided literature describes HBV as a DNA virus that affects
      the liver, causing both acute and chronic hepatitis.
  - reference: PMID:24976703
    supports: SUPPORT
    snippet: Hepatitis B virus (HBV) infection is a major cause of acute and chronic
      hepatitis, and of its long-term complications.
    explanation: The literature confirms that HBV can cause both acute and chronic
      hepatitis.
  - reference: PMID:30811163
    supports: SUPPORT
    snippet: Hepatitis B virus (HBV) is a partly double-stranded DNA virus that causes
      acute and chronic liver infection.
    explanation: The literature supports the statement that HBV is a DNA virus affecting
      the liver and causing both acute and chronic hepatitis.
transmission:
- name: Blood-borne Transmission
  description: Spread through contact with infected blood, including needlesticks
    and blood transfusions.
  evidence:
  - reference: PMID:9353819
    supports: SUPPORT
    snippet: HCWs who are exposed to the blood and body fluids of patients should
      be required to receive hepatitis B vaccine.
    explanation: The literature indicates that healthcare workers exposed to blood
      and body fluids are at risk of hepatitis B, supporting the statement that hepatitis
      B is spread through contact with infected blood.
  - reference: PMID:34806523
    supports: SUPPORT
    snippet: HBV can cause severe complications by invading these tissues.
    explanation: The complications and spread of HBV through blood and other tissues
      are discussed, supporting the statement about blood-borne transmission.
  - reference: PMID:24966613
    supports: SUPPORT
    snippet: Cells and tissues are shared between countries which have different regulations
      and laboratory equipment and represent a risk of hepatitis B virus (HBV) transmission
      that has become a global safety concern.
    explanation: The risk of HBV transmission through tissue transplants supports
      the idea of blood-borne transmission.
  - reference: PMID:38000801
    supports: SUPPORT
    snippet: Neonates experience significant risk from both vertical and horizontal
      hepatitis B exposure during a period of immaturity of the innate and adaptive
      immune systems.
    explanation: The statement about blood-borne transmission is supported by the
      risk of horizontal transmission through infected blood.
  - reference: PMID:33268600
    supports: SUPPORT
    snippet: Although the HBV vaccine can effectively prevent HBV infection, chronic
      HBV infection still endangers human health and results in a large social burden.
    explanation: The literature discusses the prevention of HBV through vaccination,
      indicating its spread through blood contact.
  - reference: PMID:23074317
    supports: SUPPORT
    snippet: We documented HBV transmission during orthopedic surgery to 2 patients
      from a surgeon with HBV.
    explanation: This study documents direct transmission of HBV through surgical
      procedures, supporting the statement about blood-borne transmission.
- name: Sexual Transmission
  description: Spread through sexual contact with an infected person.
  evidence:
  - reference: PMID:2183516
    supports: SUPPORT
    snippet: In the Western world most cases of hepatitis B virus (HBV) infection
      are acquired through sexual intercourse and through needle sharing by intravenous
      drug users (IVDU).
    explanation: The abstract clearly states that sexual intercourse is a significant
      mode of transmission for hepatitis B virus in the Western world.
  - reference: PMID:9132977
    supports: SUPPORT
    snippet: These findings suggest that sexual acquisition of hepatitis B occurs
      at low levels in Mwanza, and that HBV can be prevented through enhancement of
      the current HIV/STD control activities, in addition to improved vaccination
      strategies.
    explanation: While the study indicates that sexual transmission occurs at low
      levels in Mwanza, Tanzania, it does acknowledge that sexual acquisition of hepatitis
      B is a route of transmission.
  - reference: PMID:15647702
    supports: SUPPORT
    snippet: It is clear that sexual transmission of hepatitis B virus is still widespread
      and is a major problem in certain high-risk groups such as men who have sex
      with men, intravenous drug users, prisoners and sex workers.
    explanation: The abstract emphasizes that sexual transmission of hepatitis B is
      still a major problem in certain high-risk groups.
  - reference: PMID:30415551
    supports: SUPPORT
    snippet: Sexual and parent-to-child transmission are important routes of CHB spread
      in this population from northern Iran despite the fact that 24 years have passed
      since the beginning of hepatitis B vaccination in infants.
    explanation: The study identifies sexual transmission as an important route for
      the spread of chronic hepatitis B in Northern Iran.
- name: Mother-to-Child Transmission (Perinatal)
  description: Spread from an infected mother to her baby during childbirth.
  evidence:
  - reference: PMID:29064028
    supports: SUPPORT
    snippet: Chronic hepatitis B virus (HBV) infection due to perinatal mother-to-infant
      transmission (MTIT) remains a serious global health problem.
    explanation: The article discusses the transmission of HBV from mother to infant
      during childbirth, supporting the statement.
  - reference: PMID:33574867
    supports: SUPPORT
    snippet: The infection is most widely transmitted from the infected mother to
      a child, with infected blood and body fluids.
    explanation: This reference supports the statement by indicating that HBV is commonly
      transmitted from mother to child.
  - reference: PMID:37778777
    supports: SUPPORT
    snippet: Maternal-to-child transmission of hepatitis B virus (HBV) and hepatitis
      delta virus (HDV) can lead to the risk of progressive liver disease in infants.
    explanation: The article mentions maternal-to-child transmission of HBV, supporting
      the statement.
  - reference: PMID:22510637
    supports: SUPPORT
    snippet: Transmission of the hepatitis B virus, despite the availability of the
      vaccine, still occurs, particularly in the perinatal setting.
    explanation: The reference supports the statement by discussing the occurrence
      of HBV transmission in the perinatal setting.
  - reference: PMID:31692718
    supports: SUPPORT
    snippet: Hepatitis B is a major health concern in Ghana, where prevalence of the
      virus remains high and most chronic patients are infected during childhood or
      at birth.
    explanation: The study supports the statement by indicating that many chronic
      HBV cases are due to infections at birth, implying mother-to-child transmission.
prevalence:
- population: Global
  percentage: 3.5
  evidence:
  - reference: PMID:26231459
    supports: PARTIAL
    snippet: HBsAg seroprevalence was 3.61% (95% CI 3.61-3.61) worldwide.
    explanation: The statement claims a global prevalence of 3.5%, while the literature
      states it is 3.61%. The difference is minor, but it is not an exact match.
epidemiology:
- name: Basic Reproduction Number (R0)
  description: The average number of secondary infections caused by one infected individual
    in a completely susceptible population.
  minimum_value: 2
  maximum_value: 10
  notes: Highly variable based on geographic region, vaccination rates, and modes
    of transmission.
  factors:
  - Vaccination coverage
  - Healthcare practices
  - Population mobility
  evidence:
  - reference: PMID:37322965
    supports: PARTIAL
    snippet: In this regard, we first calculate the basic reproduction number and
      the equilibrium points of the deterministic Hepatitis B model.
    explanation: The reference discusses the calculation of the basic reproduction
      number (R0) for Hepatitis B, which supports the statement about the importance
      of R0. However, it does not provide specific values for the maximum and minimum
      R0.
  - reference: PMID:16754644
    supports: NO_EVIDENCE
    snippet: Worldwide, two billion people have been infected with hepatitis B virus
      (HBV), 360 million have chronic infection, and 600,000 die each year from HBV-related
      liver disease or hepatocellular carcinoma.
    explanation: This reference provides epidemiological data on Hepatitis B but does
      not discuss the basic reproduction number (R0) or its variability.
  - reference: PMID:7713188
    supports: NO_EVIDENCE
    snippet: The key determinants of transmission of bloodborne pathogens are the
      dose and serum viral concentration of an exposure.
    explanation: This reference focuses on the determinants of transmission of bloodborne
      pathogens, including Hepatitis B, but does not provide information on the basic
      reproduction number (R0).
- name: Effective Reproduction Number (R or Rt)
  description: The average number of secondary cases per infectious case in a population
    with some immunity or control measures.
  minimum_value: 0.3
  maximum_value: 1.2
  notes: Decreases with effective vaccination and antiviral therapies.
  factors:
  - Proportion of immune individuals
  - Effectiveness of antiviral treatment
  evidence:
  - reference: PMID:37322965
    supports: PARTIAL
    snippet: To reduce Hepatitis B infection rates and to promote vaccination rates,
      three control variables are used, for instance, isolation of patients, treatment
      of patients, and vaccine inoculation.
    explanation: The reference discusses control strategies to reduce HBV transmission,
      which indirectly supports the idea that the effective reproduction number (R
      or Rt) decreases with effective vaccination and antiviral therapies. However,
      it does not provide specific values for the effective reproduction number.
- name: Incubation Period
  unit: days
  minimum_value: 30
  maximum_value: 180
  mean_range: 60-90
  notes: Affects the timing of infection control measures and contact tracing.
  evidence:
  - reference: PMID:29260504
    supports: SUPPORT
    snippet: a hepatitis B virus (HBV) model with an incubation period and delayed
      state and control variables is firstly proposed.
    explanation: The paper discusses a model that includes the incubation period of
      Hepatitis B, which aligns with the provided statement.
- name: Chronic Carriage Rate
  description: The percentage of infected individuals who develop chronic hepatitis
    B infection.
  unit: percentage
  minimum_value: 2
  maximum_value: 10
  notes: Higher in infants and young children than in adults.
  evidence:
  - reference: PMID:11197043
    supports: PARTIAL
    snippet: Of the estimated 50 million new cases of hepatitis B virus (HBV) infection
      diagnosed annually, 5-10% of adults and up to 90% of infants will become chronically
      infected.
    explanation: The statement is partially supported as it mentions that 5-10% of
      adults develop chronic hepatitis B infection, which falls within the 2-10% range.
      However, it also states that up to 90% of infants can become chronically infected,
      which is not captured in the statement.
  - reference: PMID:12616451
    supports: PARTIAL
    snippet: Infants who acquire HBV perinatally have up to 90% risk of developing
      chronic HBV infection.
    explanation: The statement is partially supported as it mentions that infants
      have up to 90% risk of developing chronic HBV infection, but does not provide
      specific percentages for adults.
  - reference: PMID:29202763
    supports: NO_EVIDENCE
    snippet: Carrier individuals are especially significant, because they do not exhibit
      any symptoms and are able to transmit the infection.
    explanation: This reference discusses the role of carrier individuals in the transmission
      of hepatitis B but does not provide specific percentages for chronic carriage
      rates.
- name: Asymptomatic Ratio
  description: The proportion of infected individuals who do not display symptoms.
  unit: percentage
  minimum_value: 50
  maximum_value: 70
  notes: Important for understanding true disease prevalence and silent spreaders.
  evidence:
  - reference: PMID:23185500
    supports: PARTIAL
    snippet: Of 117 participants, 90% of recipients exhibited evidence of exposure
      to HBV, 42% with HBsAg and/or HBV DNA and 48% anti-HBc reactive without detectable
      HBV DNA.
    explanation: The study indicates a high exposure rate to HBV, with a significant
      proportion of individuals being asymptomatic carriers. However, it does not
      provide a specific percentage range for asymptomatic individuals.
  - reference: PMID:12616451
    supports: PARTIAL
    snippet: Many HBV-infected children have normal alanine aminotransferase values
      and minimal chronic hepatitis. Children with chronic HBV infection are usually
      asymptomatic but may develop chronic liver disease or hepatocellular carcinoma.
    explanation: The literature mentions that many children with chronic HBV infection
      are asymptomatic, but it does not specify the exact proportion of asymptomatic
      cases.
progression:
- phase: Acute
  duration: Weeks to Months
  notes: May include jaundice, fatigue, abdominal pain, and elevated liver enzymes.
  evidence:
  - reference: PMID:270889
    supports: SUPPORT
    snippet: Fatigue started median 4 weeks, abdominal symptoms median 3 weeks and
      signs of cholestasis median 2.5 weeks before peak SGPT values were reached.
    explanation: The study indicates that symptoms of acute hepatitis B, including
      fatigue and abdominal symptoms, manifest over a period of weeks, supporting
      the statement.
  - reference: PMID:3967850
    supports: SUPPORT
    snippet: The median follow-up time was 8 months (range, 1 week to 3 years). HBV
      DNA was detected in 26 (34%) patients on admission to the hospital.
    explanation: This reference suggests that acute hepatitis B can have a duration
      ranging from weeks to several months, aligning with the statement.
- phase: Chronic
  duration: Years to Decades
  notes: Continuous virus presence in the liver, which may lead to cirrhosis or liver
    cancer.
  evidence:
  - reference: PMID:18067957
    supports: SUPPORT
    snippet: The knowledge of the HBV organization and replication cycle and the availability
      of sensitive HBV-DNA assays have led to remarkable progress in our understanding
      of the natural history of chronic hepatitis B infections.
    explanation: The reference discusses the natural history of chronic hepatitis
      B infections, implying a prolonged duration.
  - reference: PMID:28468285
    supports: SUPPORT
    snippet: Chronic infection with hepatitis B virus (HBV) progresses through multiple
      phases, including immune tolerant, immune active, immune control, and, in a
      subset of patients who achieve immune control, reactivation.
    explanation: The reference outlines the prolonged nature of chronic HBV infection,
      which can last for years to decades through various phases.
  - reference: PMID:21205148
    supports: SUPPORT
    snippet: Chronic hepatitis B virus (HBV) infection is a dynamic series of interactions
      between HBV, hepatocytes and the patient&#39;s immune system. HBV replication is
      the key motor of disease progression, including the development of cirrhosis
      and hepatocellular carcinoma (HCC).
    explanation: The reference indicates the long-term nature of chronic HBV infection
      and its potential to lead to serious liver conditions over time.
  - reference: PMID:12616451
    supports: SUPPORT
    snippet: Many HBV-infected children have normal alanine aminotransferase values
      and minimal chronic hepatitis. Children with chronic HBV infection are usually
      asymptomatic but may develop chronic liver disease or hepatocellular carcinoma.
    explanation: The reference highlights that chronic HBV infection can last for
      a long duration, potentially leading to serious liver conditions.
  - reference: PMID:6994954
    supports: SUPPORT
    snippet: Fewer than 10% of cases of acute icteric HBV become chronic, but chronicity
      is more common after anicteric infections. The prognosis for chronic persistent
      hepatitis B is usually good whereas many cases of chronic active hepatitis B
      will progress to cirrhosis although the time scale may be long.
    explanation: The reference supports the statement by indicating that chronic HBV
      infection can last for years to decades, with potential progression to cirrhosis.
- phase: Cirrhosis
  duration: Variable
  notes: Chronic infection can cause liver scarring, leading to liver dysfunction.
  evidence:
  - reference: PMID:18067957
    supports: SUPPORT
    snippet: The knowledge of the HBV organization and replication cycle and the availability
      of sensitive HBV-DNA assays have led to remarkable progress in our understanding
      of the natural history of chronic hepatitis B infections.
    explanation: The statement is supported as it mentions the natural history of
      chronic hepatitis B infections, which implies variability in the duration of
      the infection.
  - reference: PMID:33545773
    supports: SUPPORT
    snippet: Patients with chronic HBV infection and an excessive drinking habit activate
      HBV-DNA which increases liver inflammation, thus accelerating the progress of
      liver cirrhosis.
    explanation: This reference supports the statement as it discusses the progression
      of chronic HBV infection to liver cirrhosis, indicating a variable duration
      of the disease progression depending on external factors like alcohol intake.
  - reference: PMID:33029534
    supports: SUPPORT
    snippet: Liver-function decompensation or hepatocellular carcinoma (HCC) gradually
      appears after chronic hepatitis B progresses to cirrhosis.
    explanation: The reference supports the statement by indicating that chronic hepatitis
      B can progress to cirrhosis, which aligns with the note about chronic infection
      causing liver scarring and dysfunction.
  - reference: PMID:32147592
    supports: SUPPORT
    snippet: In a longitudinal study of patients with chronic HBV infection, we associated
      liver fibrosis progression at week 78 of treatment with higher rates of detected
      HBV DNA.
    explanation: This reference supports the statement by discussing the progression
      of fibrosis in chronic HBV infection, indicating variability in disease duration.
  - reference: PMID:25253946
    supports: SUPPORT
    snippet: The histological end points of CAH are chronic inflammation, fibrosis
      and cirrhosis which are coupled with increased DNA synthesis in cirrhotic vs
      healthy normal livers.
    explanation: The reference supports the statement by describing the progression
      of chronic active hepatitis (CAH) to cirrhosis, indicating variability in the
      duration of disease progression.
- phase: Hepatocellular Carcinoma
  duration: Variable
  notes: Chronic infection significantly increases the risk of liver cancer.
  evidence:
  - reference: PMID:20378277
    supports: SUPPORT
    snippet: Chronic HBV infection is the most prevalent cause of this tumour, accounting
      for 55% of global cases, and 89% of those in endemic regions for HBV infection.
    explanation: The literature clearly states that chronic HBV infection significantly
      increases the risk of hepatocellular carcinoma (HCC).
  - reference: PMID:31450890
    supports: SUPPORT
    snippet: Our study revealed that HBsAg levels &gt;/= 100 IU/ml, and notably &gt;1,000
      IU/ ml, are associated with an increased risk of HCC development.
    explanation: The study shows that higher levels of hepatitis B surface antigen,
      which is indicative of chronic HBV infection, are associated with an increased
      risk of liver cancer.
  - reference: PMID:19399792
    supports: SUPPORT
    snippet: The primary adverse outcomes of chronic HBV infection are hepatocellular
      carcinoma (HCC) and cirrhosis.
    explanation: This reference confirms that chronic HBV infection significantly
      increases the risk of developing hepatocellular carcinoma.
  - reference: PMID:32931613
    supports: SUPPORT
    snippet: Hepatitis B virus (HBV) is a major cause of chronic liver disease, which
      can progress to cirrhosis, hepatocellular carcinoma, and death.
    explanation: The literature indicates that chronic HBV infection can lead to hepatocellular
      carcinoma, supporting the statement.
pathophysiology:
- name: Hepatocyte Infection and cccDNA Formation
  description: HBV enters hepatocytes via NTCP receptor binding, and viral rcDNA is converted to covalently closed circular DNA (cccDNA) which forms a stable chromatinized minichromosome in the nucleus, enabling persistent infection.
  cell_types:
  - preferred_term: Hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  biological_processes:
  - preferred_term: viral entry into host cell
    term:
      id: GO:0046718
      label: viral entry into host cell
  - preferred_term: epigenetic regulation of gene expression
    term:
      id: GO:0040029
      label: epigenetic regulation of gene expression
  downstream:
  - target: Chronic Inflammation
    description: HBV infection triggers persistent immune activation and hepatic inflammation through both innate and adaptive immune responses.
    evidence:
    - reference: PMID:34071064
      supports: SUPPORT
      snippet: Although innate and adaptive immune cells play crucial roles in controlling
        hepatitis B virus (HBV) infection, they are also accountable for inflammation
        and subsequently cause liver pathologies.
      explanation: This reference directly establishes that the immune response to HBV
        causes chronic liver inflammation.
  - target: HBV DNA Integration
    description: A fraction of viral DNA integrates into host genome at sites of DNA damage, contributing to persistent HBsAg expression and oncogenesis.
  evidence:
  - reference: PMID:33573130
    supports: SUPPORT
    snippet: Human hepatitis B virus (HBV) can cause chronic, lifelong infection of
      the liver that may lead to persistent or episodic immune-mediated inflammation
      against virus-infected hepatocytes.
    explanation: This reference confirms that HBV infects hepatocytes and leads to
      chronic inflammation.
  - reference: PMID:32866519
    supports: SUPPORT
    snippet: &#39;&#39;&#39;Hepatitis B virus (HBV) specifically infects hepatocytes and causes
      severe liver diseases.&#39;
    explanation: This reference confirms that HBV specifically infects hepatocytes.
  - reference: PMID:30518652
    supports: SUPPORT
    snippet: Distinct populations of hepatocytes infected with hepatitis B virus (HBV)
      or only harboring HBV DNA integrations coexist within an HBV chronically infected
      liver.
    explanation: This reference confirms that HBV integrates into the host genome
      within hepatocytes and persists.
  - reference: PMID:32151000
    supports: SUPPORT
    snippet: HBV is a major cause of cirrhosis and hepatocellular carcinoma.
    explanation: This reference supports the statement by indicating that HBV infection
      leads to chronic conditions such as cirrhosis, which is a form of chronic inflammation.
- name: HBV DNA Integration
  description: Integration of viral dslDNA into host genome occurs at sites of DNA damage, driving insertional mutagenesis, structural rearrangements, and activation of proto-oncogenes.
  biological_processes:
  - preferred_term: DNA integration
    term:
      id: GO:0015074
      label: DNA integration
  downstream:
  - target: Hepatocellular Carcinoma
    description: DNA integration drives oncogenesis through activation of TERT and other proto-oncogenes, genomic instability, and structural rearrangements.
  notes: Present in 85-90% of HBV-related hepatocellular carcinomas.
- name: Chronic Inflammation
  description: Persistent immune response against HBV-infected hepatocytes leads to liver damage mediated by T cells, NK cells, and Kupffer cells.
  cell_types:
  - preferred_term: CD8-positive, alpha-beta T cell
    term:
      id: CL:0000625
      label: CD8-positive, alpha-beta T cell
  - preferred_term: natural killer cell
    term:
      id: CL:0000623
      label: natural killer cell
  - preferred_term: inflammatory macrophage
    term:
      id: CL:0000863
      label: inflammatory macrophage
    description: Liver-resident macrophages (Kupffer cells)
  downstream:
  - target: Liver Fibrosis
    description: Chronic inflammation activates hepatic stellate cells leading to extracellular matrix deposition and progressive fibrosis.
    evidence:
    - reference: PMID:37041599
      supports: SUPPORT
      snippet: During chronic hepatitis B virus (HBV) infection, hepatic fibrosis is
        a serious pathological condition caused by virus-induced liver damage. The
        activation of hepatic stellate cells (HSCs) is a central event in the occurrence
        and progression of liver fibrosis.
      explanation: This reference establishes the mechanistic link between chronic HBV,
        hepatic stellate cell activation, and fibrosis development.
  - target: Cirrhosis
    description: Progressive fibrosis leads to architectural disruption and nodule formation characteristic of cirrhosis.
    evidence:
    - reference: PMID:22375524
      supports: SUPPORT
      snippet: Hepatitis B virus (HBV) infection currently accounts for approximately
        600,000 deaths per year resulting from progression of liver fibrosis to cirrhosis
        and hepatocellular carcinoma.
      explanation: This reference establishes that HBV causes progression from fibrosis
        to cirrhosis.
  evidence:
  - reference: PMID:8571172
    supports: SUPPORT
    snippet: The immune response to HBV-encoded antigens is responsible both for viral
      clearance and for disease pathogenesis during this infection.
    explanation: This reference supports that the immune response against HBV-infected
      hepatocytes contributes to liver damage, which aligns with the statement.
  - reference: PMID:34543610
    supports: SUPPORT
    snippet: Cirrhosis is widely prevalent worldwide and can be a consequence of different
      causes, such as... hepatitis B or C infection.
    explanation: This reference supports the link between chronic HBV infection and
      cirrhosis, which is a downstream effect of persistent immune response and liver
      damage.
  - reference: PMID:32147592
    supports: SUPPORT
    snippet: Progression of liver fibrosis still occurs in some patients with chronic
      hepatitis B virus (HBV) infection despite antiviral therapy.
    explanation: This reference supports that chronic HBV infection leads to liver
      fibrosis, which is a downstream effect of immune response and liver damage.
  - reference: PMID:37041599
    supports: SUPPORT
    snippet: During chronic hepatitis B virus (HBV) infection, hepatic fibrosis is
      a serious pathological condition caused by virus-induced liver damage.
    explanation: This reference supports the statement that HBV-induced liver damage
      leads to fibrosis, which is a downstream effect of chronic inflammation.
  - reference: PMID:31367154
    supports: SUPPORT
    snippet: Hepatitis B virus (HBV) infection is one the leading risk factors for
      chronic hepatitis, liver fibrosis, cirrhosis and hepatocellular cancer (HCC).
    explanation: This reference supports the link between chronic HBV infection and
      liver fibrosis/cirrhosis, which are downstream effects of immune response and
      liver damage.
- name: Immune Evasion and T Cell Exhaustion
  description: HBV evades innate immune detection through dampened TLR, cGAS-STING, and RIG-I-MAVS pathways. Chronic infection leads to T cell exhaustion with upregulation of PD-1, CTLA-4, and TIM-3 checkpoint receptors.
  cell_types:
  - preferred_term: CD8-positive, alpha-beta T cell
    term:
      id: CL:0000625
      label: CD8-positive, alpha-beta T cell
  - preferred_term: regulatory T cell
    term:
      id: CL:0000815
      label: regulatory T cell
  biological_processes:
  - preferred_term: negative regulation of T cell activation
    term:
      id: GO:0050868
      label: negative regulation of T cell activation
  - preferred_term: cGAS-STING signaling pathway
    term:
      id: GO:0061761
      label: cGAS-STING signaling pathway
  evidence:
  - reference: PMID:16461223
    supports: PARTIAL
    snippet: The immune system plays an important role in determining the outcome
      of hepatitis B virus (HBV) infection... Multispecific antiviral CD4 and CD8
      responses with a type 1 cytokine production can be observed in patients who
      recover from acute HBV infection.
    explanation: The reference supports the role of T cells in immune clearance but
      does not mention B cells.
  - reference: PMID:36936922
    supports: PARTIAL
    snippet: The clearance of HBV with virus-specific CD8 T cells is critical for
      a functional cure.
    explanation: The reference supports the role of T cells in immune clearance but
      does not mention B cells.
- name: Liver Fibrosis
  description: Chronic inflammation promotes fibrotic tissue deposition replacing
    healthy liver cells.
  downstream:
  - target: Cirrhosis
    description: Progressive fibrosis leads to complete architectural disruption and end-stage liver disease.
    evidence:
    - reference: PMID:26691189
      supports: SUPPORT
      snippet: Chronic unresolved inflammation is associated with persistent hepatic
        injury and concurrent regeneration, leading to sequential development of fibrosis,
        cirrhosis, and eventually HCC.
      explanation: This reference establishes the progression from fibrosis to cirrhosis in chronic liver disease.
  evidence:
  - reference: PMID:17613356
    supports: SUPPORT
    snippet: Liver fibrosis results from chronic damage to the liver in conjunction
      with the progressive accumulation of fibrillar extracellular matrix proteins.
    explanation: The statement is supported as liver fibrosis involves the replacement
      of healthy liver cells with fibrotic tissue due to chronic inflammation.
  - reference: PMID:33528280
    supports: SUPPORT
    snippet: Chronic inflammation involves CCL11 and IL-13 to facilitate the development
      of liver cirrhosis and fibrosis in chronic hepatitis B virus infection.
    explanation: The statement is supported as chronic inflammation promotes liver
      fibrosis through specific inflammatory pathways.
  - reference: PMID:26691189
    supports: SUPPORT
    snippet: Chronic unresolved inflammation is associated with persistent hepatic
      injury and concurrent regeneration, leading to sequential development of fibrosis,
      cirrhosis, and eventually HCC.
    explanation: The statement is supported as chronic inflammation leads to liver
      fibrosis and cirrhosis.
  - reference: PMID:31769518
    supports: SUPPORT
    snippet: Recurrent hepatitis activity during chronic hepatitis B virus infection
      results in fibrosis and even hepatocellular carcinoma.
    explanation: The statement is supported as recurrent inflammation in chronic HBV
      infection results in liver fibrosis.
- name: Cirrhosis
  description: Extensive fibrosis and scarring significantly impair liver function.
  evidence:
  - reference: PMID:17981234
    supports: SUPPORT
    snippet: Untreated, chronic hepatitis B acquired early in life results in cirrhosis,
      liver failure, or hepatocellular carcinoma in up to 40% of individuals.
    explanation: This reference supports the statement by indicating that chronic
      hepatitis B can lead to cirrhosis, which is associated with extensive fibrosis
      and scarring that impair liver function.
  - reference: PMID:19577114
    supports: SUPPORT
    snippet: Cirrhosis is defined histologically as an advanced form of progressive
      hepatic fibrosis with distortion of the hepatic architecture and regenerative
      nodule formation.
    explanation: This reference supports the statement by describing cirrhosis as
      an advanced form of hepatic fibrosis that distorts liver architecture, thereby
      impairing liver function.
  - reference: PMID:17613356
    supports: PARTIAL
    snippet: Liver fibrosis results from chronic damage to the liver in conjunction
      with the progressive accumulation of fibrillar extracellular matrix proteins.
    explanation: While this reference discusses liver fibrosis resulting from chronic
      liver damage, it does not explicitly connect it to cirrhosis or the impairment
      of liver function.
  - reference: PMID:24373083
    supports: SUPPORT
    snippet: Long-lasting HBV-DNA suppression is considered to be the best surrogate
      end-point of antiviral therapy in patients with hepatitis B virus (HBV) related
      chronic hepatitis or cirrhosis, and it is a prerequisite to prevent liver-related
      complications and improve survival.
    explanation: This reference supports the statement by mentioning cirrhosis in
      the context of chronic hepatitis B and its associated liver-related complications.
phenotypes:
- category: Gastrointestinal
  name: Jaundice
  description: Yellowing of the skin and eyes due to elevated bilirubin levels from impaired liver function.
  frequency: FREQUENT
  notes: Due to liver dysfunction causing elevated bilirubin levels
  evidence:
  - reference: PMID:24266913
    supports: SUPPORT
    snippet: Chronically infected patients should be followed on a regular basis,
      preferably every 6 months, with liver function tests, and when appropriate,
      HBV DNA levels. Those who meet the criteria for high risk for HCC should undergo
      liver ultrasound every 6 months. Powerful antiviral medications are available
      that can suppress but not cure HBV and result in resolution of liver inflammation
      and fibrosis, even cirrhosis, as well as decrease the risk of developing HCC.
    explanation: The literature mentions the management of chronic Hepatitis B and
      its effects on liver function, which can lead to jaundice.
  - reference: PMID:3050928
    supports: SUPPORT
    snippet: The classic presenting symptoms of viral hepatitis are jaundice, nausea,
      vomiting, malaise, anorexia, and dull right upper quadrant pain.
    explanation: The literature explicitly lists jaundice as a classic presenting
      symptom of viral hepatitis, including Hepatitis B.
  - reference: PMID:34835022
    supports: SUPPORT
    snippet: Hepatitis B virus (HBV) infection is one of the serious health problems
      in the world as HBV causes severe liver diseases.
    explanation: The literature discusses the severe liver diseases caused by Hepatitis
      B, which can lead to jaundice due to liver dysfunction.
  - reference: PMID:35395817
    supports: SUPPORT
    snippet: This case report describes a 57-year-old Iranian woman admitted to the
      hospital with jaundice, fever, body itching, abdominal pain, progressive muscle
      weakness, icteric sclera, right upper quadrant pain, and decreased muscle force.
    explanation: The case report describes a patient with Hepatitis B presenting with
      jaundice, supporting the statement that jaundice is a frequent symptom due to
      liver dysfunction.
  phenotype_term:
    preferred_term: Jaundice
    term:
      id: HP:0000952
      label: Jaundice
- category: Systemic
  name: Fatigue
  description: Persistent tiredness and weakness commonly experienced by patients with chronic hepatitis B infection.
  frequency: FREQUENT
  evidence:
  - reference: PMID:7493307
    supports: SUPPORT
    snippet: Hepatitis cases scored significantly higher fatigue scores, GHQ-12 scores
      and muscle pain scores.
    explanation: The study indicates that fatigue is more common after recovery in
      patients hospitalized for hepatitis B up to 30 months post-infection compared
      with matched controls hospitalized for other infectious diseases.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
- category: Gastrointestinal
  name: Abdominal Pain
  description: Right upper quadrant pain or discomfort related to hepatic inflammation and liver capsule distension.
  frequency: OCCASIONAL
  notes: May be related to liver inflammation
  evidence:
  - reference: PMID:24954675
    supports: SUPPORT
    snippet: Hepatitis B virus is not cytopathic; both liver damage and viral control--and
      therefore clinical outcome--depend on the complex interplay between virus replication
      and host immune response.
    explanation: The literature mentions liver damage and clinical outcomes related
      to Hepatitis B, which can include gastrointestinal symptoms like abdominal pain
      due to liver inflammation.
  - reference: PMID:3050928
    supports: SUPPORT
    snippet: The classic presenting symptoms of viral hepatitis are jaundice, nausea,
      vomiting, malaise, anorexia, and dull right upper quadrant pain.
    explanation: The literature lists dull right upper quadrant pain as a classic
      symptom of viral hepatitis, which includes Hepatitis B, supporting the statement
      that abdominal pain is an occasional gastrointestinal symptom related to liver
      inflammation.
  phenotype_term:
    preferred_term: Abdominal pain
    term:
      id: HP:0002027
      label: Abdominal pain
- category: Hepatic
  name: Elevated Liver Enzymes
  description: Increased serum levels of ALT and AST indicating hepatocyte injury and ongoing liver inflammation.
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Reflects liver cell damage and is a key diagnostic feature
  evidence:
  - reference: PMID:34835022
    supports: SUPPORT
    snippet: The HBV surface antigen (HBsAg)-positive group had a more frequent prevalence
      of patients with higher transaminase elevations than the HBsAg-negative group.
    explanation: The study indicates that elevated liver enzymes, which reflect liver
      cell damage, are more frequently observed in patients with Hepatitis B virus
      infection.
  - reference: PMID:30418344
    supports: SUPPORT
    snippet: Abnormal liver enzymes are frequently encountered in primary care offices
      and hospitals and may be caused by a wide variety of conditions, from mild and
      nonspecific to well-defined and life-threatening.
    explanation: Elevated liver enzymes are a common diagnostic feature in various
      liver diseases, including Hepatitis B.
  - reference: PMID:29551632
    supports: SUPPORT
    snippet: The prevalence of hepatitis B surface antigen (HBsAg) was 18.5% (126/680)
      and of liver cirrhosis was 9.4% (64/680).
    explanation: The presence of elevated liver enzymes is associated with Hepatitis
      B infection, as indicated by the prevalence of HBsAg in patients.
  - reference: PMID:33418899
    supports: SUPPORT
    snippet: Globally, hepatitis B virus (HBV) related hepatocellular carcinoma (HCC)
      is one of the major causes of cancer-related mortality.
    explanation: Although the focus is on hepatocellular carcinoma, the study implies
      the role of Hepatitis B in causing severe liver conditions, which include elevated
      liver enzymes as a diagnostic feature.
  - reference: PMID:3050928
    supports: SUPPORT
    snippet: Studies are done for the elevated transaminase levels that are characteristic
      of hepatitis infection.
    explanation: Elevated transaminase levels are characteristic of hepatitis infections,
      including Hepatitis B.
- category: Gastrointestinal
  frequency: FREQUENT
  name: Nausea
  description: Feeling of sickness with inclination to vomit, common during acute hepatitis B infection.
  evidence:
  - reference: PMID:3050928
    supports: SUPPORT
    snippet: The classic presenting symptoms of viral hepatitis are jaundice, nausea,
      vomiting, malaise, anorexia, and dull right upper quadrant pain.
    explanation: The literature explicitly mentions nausea as a classic presenting
      symptom of viral hepatitis, which includes Hepatitis B.
  phenotype_term:
    preferred_term: Nausea
    term:
      id: HP:0002018
      label: Nausea
- category: Gastrointestinal
  frequency: FREQUENT
  name: Vomiting
  description: Forceful expulsion of stomach contents, often accompanying nausea in acute hepatitis B.
  evidence:
  - reference: PMID:3050928
    supports: PARTIAL
    snippet: The classic presenting symptoms of viral hepatitis are jaundice, nausea,
      vomiting, malaise, anorexia, and dull right upper quadrant pain.
    explanation: The reference mentions vomiting as one of the classic presenting
      symptoms of viral hepatitis, which includes Hepatitis B. However, it does not
      specify the frequency, so it partially supports the statement.
  phenotype_term:
    preferred_term: Vomiting
    term:
      id: HP:0002013
      label: Vomiting
- category: Systemic
  frequency: OCCASIONAL
  name: Fever
  description: Elevated body temperature that may occur during acute HBV infection or flares of chronic disease.
  evidence:
  - reference: PMID:28223176
    supports: PARTIAL
    snippet: Prodromal fever indicated more severe liver injury and was independently
      associated with hepatitis B e antigen (HBeAg) negativity.
    explanation: The study indicates that fever can be associated with acute hepatitis
      B, particularly in severe cases, but it does not explicitly categorize fever
      as an occasional systemic manifestation.
  - reference: PMID:34913875
    supports: PARTIAL
    snippet: Several of these extrahepatic syndromes have been well described, including
      systemic vasculitides, glomerulonephritis, and cutaneous manifestations.
    explanation: While the reference mentions systemic manifestations of hepatitis
      B, it does not specifically mention fever as one of them.
  - reference: PMID:35499229
    supports: PARTIAL
    snippet: The study confirms the endemicity of hepatitis B and enteric fever in
      the area.
    explanation: The study mentions the prevalence of hepatitis B among febrile patients
      but does not specifically categorize fever as an occasional systemic manifestation
      of hepatitis B.
  phenotype_term:
    preferred_term: Fever
    term:
      id: HP:0001945
      label: Fever
- category: Hepatic
  frequency: OCCASIONAL
  name: Hepatomegaly
  description: Enlargement of the liver detectable on physical examination or imaging, indicating hepatic inflammation.
  notes: Liver enlargement
  evidence:
  - reference: PMID:12150847
    supports: SUPPORT
    snippet: Occult hepatitis B occurs in a number of clinical settings.
    explanation: While the abstract does not specifically mention hepatomegaly as
      a frequent symptom, it implies that various liver-related conditions are associated
      with hepatitis B, supporting the occasional occurrence of hepatomegaly.
  - reference: PMID:19682192
    supports: PARTIAL
    snippet: Severe acute exacerbation is a unique presentation of chronic hepatitis
      B characterized by very high alanine aminotransferase level accompanied by jaundice
      and hepatic decompensation.
    explanation: The text describes severe liver conditions related to chronic hepatitis
      B, but does not directly mention hepatomegaly. It suggests severe liver involvement,
      which could include hepatomegaly.
  phenotype_term:
    preferred_term: Hepatomegaly
    term:
      id: HP:0002240
      label: Hepatomegaly
- category: Systemic
  frequency: OCCASIONAL
  name: Arthralgias
  description: Joint pain without joint swelling, an extrahepatic manifestation of HBV infection.
  notes: Joint pain
  evidence:
  - reference: PMID:18760074
    supports: SUPPORT
    snippet: The most commonly described include skin rash, arthritis, arthralgia,
      glomerulonephritis, polyarteritis nodosa, and papular acrodermatitis etc.
    explanation: The reference confirms that arthralgia (joint pain) is a commonly
      described extrahepatic manifestation of Hepatitis B.
  phenotype_term:
    preferred_term: Arthralgias
    term:
      id: HP:0002829
      label: Arthralgia
- category: Dermatologic
  frequency: OCCASIONAL
  name: Rash
  description: Skin eruptions that may occur as an extrahepatic manifestation of HBV infection.
  evidence:
  - reference: PMID:6133886
    supports: SUPPORT
    snippet: Dermatologic manifestations of hepatitis B virus infection.
    explanation: The title of the reference directly indicates the presence of dermatologic
      manifestations, supporting the statement that hepatitis B can cause occasional
      dermatologic conditions like rash.
  - reference: PMID:1185334
    supports: SUPPORT
    snippet: The association of arthritis, arthralgia, and various types of skin rashes,
      as a prodrome to viral hepatitis, although well recognized in adults, has not
      been well described in children.
    explanation: The reference mentions that skin rashes are recognized as prodromal
      manifestations of viral hepatitis, including hepatitis B, supporting the statement.
  - reference: PMID:1532114
    supports: SUPPORT
    snippet: The most frequent adverse reactions were myalgia/arthralgia lasting longer
      than 3 days (14), followed by skin rashes (eight) and dizziness (seven).
    explanation: The reference notes that skin rashes were among the most frequent
      adverse reactions to the hepatitis B vaccine, indicating that hepatitis B can
      be associated with dermatologic manifestations like rash.
  phenotype_term:
    preferred_term: Skin rash
    term:
      id: HP:0000988
      label: Skin rash
biochemical:
- name: Hepatitis B Surface Antigen (HBsAg)
  presence: Positive
  context: Indicates active infection
  evidence:
  - reference: PMID:49464
    supports: SUPPORT
    snippet: HBsAg in an individual indicates that he harbors the virus of hepatitis
      B; it may be present in the absence of liver disease or be found in association
      with both acute and chronic type B hepatitis.
    explanation: The presence of HBsAg indicates that the individual harbors the hepatitis
      B virus, which supports the statement that a positive HBsAg indicates an active
      infection.
  - reference: PMID:22300111
    supports: SUPPORT
    snippet: To analyze the epidemiological, clinical, and virological characteristics
      of patients newly diagnosed with active hepatitis B virus (HBV) infection based
      on the presence of positive hepatitis B surface antigen (HBsAg)...
    explanation: The study focuses on patients newly diagnosed with active HBV infection
      based on the presence of positive HBsAg, supporting the statement that a positive
      HBsAg indicates an active infection.
  - reference: PMID:21692954
    supports: SUPPORT
    snippet: Serum hepatitis B surface antigen (HBsAg) levels reflect intrahepatic
      hepatitis B virus (HBV) covalently closed circular DNA and may be a valuable
      addition to HBV DNA in the management of patients with chronic hepatitis B (CHB).
    explanation: The presence of HBsAg reflects the presence of hepatitis B virus,
      indicating active infection, which supports the statement.
  - reference: PMID:36906494
    supports: SUPPORT
    snippet: The Advisory Committee for Immunization Practices (ACIP) recommends testing
      all pregnant women for hepatitis B surface antigen (HBsAg) and testing HBsAg-positive
      pregnant women for hepatitis B virus deoxyribonucleic acid (HBV DNA).
    explanation: The recommendation to test HBsAg-positive individuals for HBV DNA
      indicates that a positive HBsAg is associated with active infection.
- name: Hepatitis B e Antigen (HBeAg)
  presence: Positive
  context: Indicates active viral replication and high infectivity
  evidence:
  - reference: PMID:12124405
    supports: SUPPORT
    snippet: The presence of hepatitis B e antigen (HBeAg) in serum indicates active
      viral replication in hepatocytes.
    explanation: The study confirms that HBeAg is a surrogate marker for active hepatitis
      B virus replication.
  - reference: PMID:21205143
    supports: SUPPORT
    snippet: HBeAg seropositivity is a marker for active viral replication.
    explanation: The article states that HBeAg is associated with highly replicative
      activity of the hepatitis B virus.
  - reference: PMID:7038074
    supports: SUPPORT
    snippet: Hepatitis B virus markers were studied in serum and liver of 24 children
      with chronic hepatitis. All patients had evidence of active virus replication...
      Furthermore, 19 of 24 patients had hepatitis B e antigen in serum.
    explanation: The study shows that the presence of HBeAg in serum is associated
      with active hepatitis B virus replication.
  - reference: PMID:25218700
    supports: SUPPORT
    snippet: Hepatitis B e antigen (HBeAg) is a marker to indicate active replication
      of hepatitis B virus (HBV).
    explanation: The article confirms that HBeAg is an indicator of active HBV replication.
- name: HBV DNA
  presence: Positive
  context: Indicates viral load and active replication
  evidence:
  - reference: PMID:7030903
    supports: SUPPORT
    snippet: The assay for serum HBV DNA appears to be an excellent noninvasive method
      for detecting active replication of HBV in HBsAg carriers.
    explanation: The presence of HBV DNA in the serum is associated with active replication
      of HBV in the liver.
  - reference: PMID:31741331
    supports: SUPPORT
    snippet: Hepatitis B virus (HBV) is a DNA virus, belonging to the Hepadnaviridae
      family.
    explanation: The presence of HBV DNA indicates the presence of the virus and hence
      active replication.
  - reference: PMID:27032097
    supports: SUPPORT
    snippet: Quantitative real-time PCR and HBV sequencing were performed in HBsAg-positive
      patients.
    explanation: The presence of HBV DNA in serum is used to quantify viral load,
      indicating active replication.
  - reference: PMID:35122363
    supports: SUPPORT
    snippet: Use of HBV DNA and liver stiffness in predicting clinical events in patients
      with chronic hepatitis B.
    explanation: HBV DNA levels are used to monitor and predict disease progression,
      indicating active replication.
  - reference: PMID:29170913
    supports: SUPPORT
    snippet: &#39;Maternal serum HBeAg was a risk factor of PBMC HBV rcDNA (OR = 3.896,
      95% CI: 1.929-7.876) and PBMC HBV cccDNA (OR = 3.74, 95% CI: 1.186-11.793) in
      the HBsAg-positive mothers.&#39;
    explanation: The presence of HBV DNA in serum and PBMC is linked to active viral
      replication.
  - reference: PMID:31021394
    supports: SUPPORT
    snippet: HBV DNA levels in pregnancy women at 28-30 weeks predict the risk of
      immunoprophylaxis failure.
    explanation: HBV DNA quantification is used to predict viral load and active replication.
  - reference: PMID:22510145
    supports: SUPPORT
    snippet: Serum HBV DNA level has been shown to be significantly and independently
      associated with incidence of hepatocellular carcinoma (HCC) and cirrhosis and
      liver-related mortality across a biological gradient.
    explanation: The presence of HBV DNA in serum indicates active viral replication
      and disease progression.
  - reference: PMID:28350873
    supports: SUPPORT
    snippet: Our results demonstrated that on-treatment HBV DNA could probably predict
      VBT in ETV-treated HBeAg-positive chronic hepatitis B patients.
    explanation: HBV DNA levels are used to monitor viral load and active replication.
  - reference: PMID:37179582
    supports: SUPPORT
    snippet: HBV DNA level is a negative risk factor for liver disease progression.
    explanation: The presence of HBV DNA indicates active replication and can be used
      to assess disease severity.
genetic:
- name: HBV Genotype
  presence: Multiple Genotypes (A-H)
  notes: Influences disease progression and treatment response
  evidence:
  - reference: PMID:19072424
    supports: SUPPORT
    snippet: There are eight different genotypes named A-H. Genotypes have distinct
      geographic distribution in different regions of the world. There exists a difference
      in the disease profile between different genotypes.
    explanation: The reference supports the presence of multiple HBV genotypes (A-H)
      and indicates that these genotypes influence disease progression and treatment
      response.
  - reference: PMID:26255971
    supports: SUPPORT
    snippet: The clinical course of hepatitis B virus (HBV) infection greatly differs
      in individuals. Various viral, host, and environmental factors influence the
      natural history of HBV infection.
    explanation: The reference supports the influence of various factors, including
      viral genotypes, on the clinical course of HBV infection.
  - reference: PMID:34593148
    supports: SUPPORT
    snippet: Various HBV genotypes and their impact on the clinical course are discussed.
      The relationship of HBV serologies and HBV DNA to disease progression is outlined.
    explanation: The reference supports the statement that different HBV genotypes
      influence disease progression and treatment response.
diagnosis:
- name: HBsAg Test
  description: Blood test detecting Hepatitis B surface antigen, the earliest serological marker of infection.
  presence: Positive
  notes: Indicates current hepatitis B infection
  evidence:
  - reference: PMID:21739440
    supports: SUPPORT
    snippet: The prevalence of HBsAg positivity among subjects decreased from 16.3%
      in the adults to 5.2% in the graduate students and then to 2.8% for the undergraduate
      students (P = 0.0007).
    explanation: HBsAg positivity indicates current hepatitis B infection, as discussed
      in the study.
  - reference: PMID:37001946
    supports: SUPPORT
    snippet: Chronic HBV is diagnosed with positive HBsAg and detectable HBV DNA.
    explanation: The presence of HBsAg is used to diagnose chronic hepatitis B virus
      infection.
  - reference: PMID:25218700
    supports: SUPPORT
    snippet: Occult HBV infection (OBI), referred to persistence of HBV DNA in serum
      and/or liver without detectable serum hepatitis B surface (HBsAg), usually has
      low HBV DNA levels.
    explanation: The presence of HBsAg typically indicates active hepatitis B infection,
      as its absence in OBI is noted as unusual.
  - reference: PMID:22300111
    supports: SUPPORT
    snippet: To analyze the epidemiological, clinical, and virological characteristics
      of patients newly diagnosed with active hepatitis B virus (HBV) infection based
      on the presence of positive hepatitis B surface antigen (HBsAg).
    explanation: The study focuses on diagnosing active hepatitis B infection by the
      presence of HBsAg.
- name: HBeAg Test
  description: Blood test detecting Hepatitis B e antigen, a marker of active viral replication and high infectivity.
  presence: Positive
  notes: Indicates high levels of viral replication
  evidence:
  - reference: PMID:25218700
    supports: SUPPORT
    snippet: &#39;BACKGROUND: Hepatitis B e antigen (HBeAg) is a marker to indicate active
      replication of hepatitis B virus (HBV).&#39;
    explanation: HBeAg is indeed a marker used to indicate active replication of HBV,
      supporting the statement that a positive HBeAg test indicates high levels of
      viral replication.
  - reference: PMID:20512987
    supports: PARTIAL
    snippet: HBeAg correlated with serum HBV DNA (r = 0.60, P &lt; 0.0001), although
      emerging BCP/PC variants reduced HBeAg titer independent of viral replication.
    explanation: While HBeAg generally correlates with high levels of viral replication,
      there are instances where emerging viral variants can reduce HBeAg levels independent
      of viral replication, indicating that the correlation is not absolute.
  - reference: PMID:29869595
    supports: PARTIAL
    snippet: Alternatively, HBV e antigen (HBeAg) may accurately indicate high viral
      replication.
    explanation: HBeAg can indicate high viral replication, but the prevalence of
      HBeAg in highly viremic patients was low, suggesting that not all high viral
      replication cases will test positive for HBeAg.
- name: HBV DNA Test
  description: PCR-based test that quantifies HBV DNA in blood to measure viral load.
  presence: Positive
  notes: Measures viral load in the blood
  evidence:
  - reference: PMID:12776281
    supports: SUPPORT
    snippet: HBV DNA was measured using the Amplicor HBV Monitor Test (Roche Diagnostics,
      Branchburg, NJ), an in vitro assay using polymerase chain reaction nucleic acid
      amplification and DNA hybridization for the quantitative measurement of HBV
      DNA in serum.
    explanation: This study confirms that the HBV DNA test measures viral load in
      the blood of hepatitis B patients.
  - reference: PMID:33453301
    supports: SUPPORT
    snippet: Estimation of hepatitis B (HBV) viral load (VL) is critical in hepatitis-B
      cascade-of-care and at present there is no point of care (POC) molecular assay
      available for the same.
    explanation: The study discusses the importance of estimating HBV viral load,
      which is done through testing HBV DNA.
  - reference: PMID:38163269
    supports: SUPPORT
    snippet: Accurate detection and quantification of HBV DNA in the blood are essential
      for diagnosing and monitoring HBV infection. The most common method for detecting
      HBV DNA is real-time PCR, which can be used to detect the virus and assess the
      viral load to monitor the response to antiviral therapy.
    explanation: This reference supports that the HBV DNA test measures viral load
      in the blood.
  - reference: PMID:32360825
    supports: SUPPORT
    snippet: We assessed the performance of a novel immunoassay, HBV core-related
      antigen (HBcrAg), as a low-cost (less than US $15/assay) alternative to nucleic
      acid testing to indicate clinically important high viremia in chronic HBV patients
      infected with different genotypes.
    explanation: The study mentions nucleic acid testing (which includes HBV DNA tests)
      as a method to measure viral load in the blood.
- name: Liver Biopsy
  description: Tissue sampling procedure to directly assess liver histology for inflammation, fibrosis, and cirrhosis.
  notes: Assesses liver damage and fibrosis
  evidence:
  - reference: PMID:17613355
    supports: SUPPORT
    snippet: Liver biopsy has been a major diagnostic tool in the evaluation of individuals
      with chronic hepatitis for many decades and remains the most direct way of visualizing
      hepatic necroinflammation and fibrosis.
    explanation: The reference clearly states that liver biopsy is a major diagnostic
      tool for visualizing hepatic necroinflammation and fibrosis, thus supporting
      the statement.
  - reference: PMID:35240329
    supports: SUPPORT
    snippet: Transient elastography was performed at a mean final age of 38.21 years
      to identify advanced fibrosis.
    explanation: Although the primary focus is on transient elastography, the study
      context implies that liver biopsy is a standard method for assessing liver fibrosis.
  - reference: PMID:23808910
    supports: SUPPORT
    snippet: Present study was designed to correlate fibroscan with liver biopsy and
      determine whether fibroscan can avoid liver biopsy in patients with CHB.
    explanation: The study compares fibroscan with liver biopsy, indicating that liver
      biopsy is a standard method for assessing liver fibrosis.
  - reference: PMID:36458851
    supports: SUPPORT
    snippet: Liver biopsy remains the gold standard for staging of liver fibrosis
      and grading of histological activity and should remain central for diagnostic
      purposes.
    explanation: The reference confirms that liver biopsy is the gold standard for
      assessing liver fibrosis, supporting the statement.
environmental:
- name: Poor Sterile Practices
  description: Inadequate infection control in healthcare settings increases HBV transmission through contaminated needles, surgical instruments, and blood products.
  notes: Increases the risk of transmission via medical procedures
  evidence:
  - reference: PMID:20123446
    supports: SUPPORT
    snippet: Increasing recognition of outbreaks involving patient-to-patient spread
      of hepatitis B and hepatitis C virus infections, however, has uncovered a disturbing
      trend. This article highlights the importance of basic infection control and
      the need for increased awareness of safe injection practices.
    explanation: The article indicates that poor sterile practices can lead to patient-to-patient
      spread of hepatitis B, supporting the statement that poor sterile practices
      increase the risk of transmission via medical procedures.
  - reference: PMID:10840606
    supports: SUPPORT
    snippet: Cases with the highest number of transmissions (one anesthesiologist
      with 217 HC transmissions, and one EEG technologist with 75 HB transmissions)
      were attributed to poor infection control practices.
    explanation: The report documents numerous cases of hepatitis B transmission attributed
      to poor infection control practices, supporting the statement.
  - reference: PMID:23074317
    supports: SUPPORT
    snippet: We documented HBV transmission during orthopedic surgery to 2 patients
      from a surgeon with HBV. This investigation highlights the importance of evaluating
      individuals who do not respond to 2 series of HBV vaccination, the increased
      risk of HBV transmission from providers with high viral loads, and the need
      to evaluate the clinical practice of providers with HBV and implement appropriate
      procedure-based practice restrictions.
    explanation: The study demonstrates that poor sterile practices and high viral
      loads in healthcare providers can lead to the transmission of hepatitis B during
      medical procedures.
- name: High-risk Behaviors
  description: Behavioral risk factors including unprotected sexual intercourse, intravenous drug use with shared needles, and occupational exposure to blood.
  notes: Includes unprotected sexual contact and intravenous drug use
  evidence:
  - reference: PMID:2183516
    supports: SUPPORT
    snippet: In the Western world most cases of hepatitis B virus (HBV) infection
      are acquired through sexual intercourse and through needle sharing by intravenous
      drug users (IVDU).
    explanation: The literature explicitly mentions that HBV infection is commonly
      acquired through sexual intercourse and needle sharing, which aligns with the
      statement&#39;s mention of unprotected sexual contact and intravenous drug use as
      high-risk behaviors.
  - reference: PMID:20411413
    supports: SUPPORT
    snippet: Sex with multiple partners, sex under the influence of alcohol or drugs,
      and unprotected sex were the most prevalent HIV risk behaviors.
    explanation: Although this reference primarily discusses HIV, it also notes that
      unprotected sex is a prevalent risk behavior, which supports the statement regarding
      high-risk behaviors for HBV.
  - reference: PMID:32338365
    supports: SUPPORT
    snippet: People who inject drugs (PWIDs) are prone to a number of blood-borne
      viral infections. Hepatitis B virus (HBV) and hepatitis C virus (HCV) constitute
      an important public health concern in this high risk group.
    explanation: The literature states that people who inject drugs are at high risk
      for HBV, supporting the statement that intravenous drug use is a high-risk behavior
      for HBV.
  - reference: PMID:27364104
    supports: SUPPORT
    snippet: The possibility of the HBV infection risk during the exposure was found
      in 25 cases and was significantly more frequent in the group III.
    explanation: This reference indicates that exposure to HBV infection is a significant
      risk, supporting the statement of high-risk behaviors related to HBV.
treatments:
- name: Antiviral Medications
  description: Includes drugs like tenofovir and entecavir to suppress HBV replication.
  evidence:
  - reference: PMID:26732483
    supports: SUPPORT
    snippet: Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have been recommended
      as the first-line anti-HBV drugs for excellent viral suppression with a low
      risk of antiviral resistance.
    explanation: The reference explicitly mentions tenofovir and entecavir as first-line
      drugs for suppressing HBV replication.
  - reference: PMID:26054819
    supports: SUPPORT
    snippet: Since 2008, it has also been indicated for treatment of chronic HBV infection
      or HIV/HBV co-infection. The aim of the treatment consists in suppressing viral
      replication, thus reducing hepatic complications and improving patient survival.
    explanation: The reference supports the use of tenofovir for suppressing HBV replication.
  - reference: PMID:32050881
    supports: SUPPORT
    snippet: The aim of this study was to evaluate the histological, virological,
      serological and biochemical response rates in CHB patients receiving tenofovir
      or entecavir therapy.
    explanation: The study evaluates the effects of tenofovir and entecavir in CHB
      patients, supporting their role in HBV suppression.
  - reference: PMID:27742007
    supports: SUPPORT
    snippet: This is achievable by the highly active antivirals, entecavir and tenofovir,
      which are considered first-line therapy in most patients with immune active
      hepatitis C virus and after liver transplantation to prevent HBV recurrence.
    explanation: The reference confirms that tenofovir and entecavir are used to suppress
      HBV replication.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Interferon Therapy
  description: Boosts the immune system to fight the virus.
  evidence:
  - reference: PMID:25034484
    supports: PARTIAL
    snippet: Interferon-alpha (IFN-alpha) therapy can convert CHB into inactive hepatitis
      B virus (HBV) infection in 20-30% of the treated patients...IFN-alpha has multiple
      antiviral, antiproliferative, and immunomodulatory activities.
    explanation: The literature indicates that Interferon-alpha has immunomodulatory
      activities, which can help in controlling HBV infection, but it does not explicitly
      state that it &#39;boosts&#39; the immune system in the general sense.
  - reference: PMID:16461223
    supports: PARTIAL
    snippet: Therapeutic strategies aimed at correcting this defective T cell reactivity
      could represent a complementary approach to the cure of chronic HBV infection.
    explanation: The literature suggests that targeting immune responses is a strategy
      in treating HBV, but it does not explicitly state that Interferon Therapy &#39;boosts&#39;
      the immune system.
  - reference: PMID:10804945
    supports: PARTIAL
    snippet: We found IFN to be a safe and adequate mode of treatment in children
      with chronic HBV infection, regardless of their liver histology and transaminase
      levels.
    explanation: The study indicates that Interferon Therapy is effective in treating
      HBV in children, but it does not explicitly state that it &#39;boosts&#39; the immune
      system.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Liver Transplant
  description: For end-stage liver disease.
  evidence:
  - reference: PMID:29125261
    supports: SUPPORT
    snippet: Liver transplantation (LT) is the only effective treatment for hepatitis
      B-virus (HBV) related end stage liver disease...
    explanation: This reference explicitly states that liver transplantation is the
      only effective treatment for end-stage liver disease caused by hepatitis B.
  - reference: PMID:17981234
    supports: SUPPORT
    snippet: Until recently, the options for a patient who had end-stage hepatitis
      B cirrhosis were severely limited, but during the past 15 years great strides
      have been made in prevention and treatment of hepatitis B cirrhosis.
    explanation: The reference discusses the advancements in treatment options for
      end-stage hepatitis B cirrhosis, implying liver transplantation as a viable
      option.
  treatment_term:
    preferred_term: organ transplantation
    term:
      id: MAXO:0010039
      label: organ transplantation
- name: Regular Monitoring
  description: Monitoring liver function and viral load to manage chronic infection.
  evidence:
  - reference: PMID:24266913
    supports: SUPPORT
    snippet: Chronically infected patients should be followed on a regular basis,
      preferably every 6 months, with liver function tests, and when appropriate,
      HBV DNA levels.
    explanation: The literature supports regular monitoring of liver function and
      viral load in patients with chronic hepatitis B infection.
  - reference: PMID:12776281
    supports: SUPPORT
    snippet: Periodic testing for HBV DNA to assess the virological status of HBsAg-positive
      dialysis patients is recommended.
    explanation: The study recommends regular monitoring of viral load in hepatitis
      B patients, supporting the statement.
  - reference: PMID:33467927
    supports: SUPPORT
    snippet: This manuscript summarized traditional biomarkers of different hepatitis
      B stages and recent-developed POCT platforms (including microfluidic platforms
      and lateral-flow strips) and discuss the challenges associated with their use.
    explanation: The article discusses the importance of monitoring hepatitis B using
      various biomarkers, which aligns with the statement.
  - reference: PMID:31528100
    supports: SUPPORT
    snippet: HBcrAg is an excellent monitor of hepatic histological changes, especially
      in CHB patients treated with nucleoside analogs.
    explanation: The literature highlights the importance of monitoring liver-related
      biomarkers in chronic hepatitis B patients.
  - reference: PMID:26799653
    supports: SUPPORT
    snippet: As a result, regular monitoring of the response during treatment and
      after treatment is required.
    explanation: The article emphasizes the necessity of regular monitoring in the
      management of chronic hepatitis B.
  - reference: PMID:33945063
    supports: SUPPORT
    snippet: Regular monitoring and treatment of chronic hepatitis B (CHB) are known
      to reduce the risk of hepatocellular carcinoma.
    explanation: The literature supports regular monitoring as a vital part of managing
      chronic hepatitis B to reduce complications.
- name: Vaccination
  description: Hepatitis B vaccine provides prevention for uninfected individuals.
  evidence:
  - reference: PMID:10776195
    supports: SUPPORT
    snippet: Immunization of all newborn infants and adolescents for HBV is a vital
      step toward eradicating HBV from the general population.
    explanation: The article supports the statement by emphasizing the importance
      of immunizing infants and adolescents to prevent HBV infection.
  - reference: PMID:33200362
    supports: SUPPORT
    snippet: Primary prevention by HBV vaccination targeting the general population
      starting from birth dose.
    explanation: The article confirms that HBV vaccination is a primary prevention
      strategy for the general population.
  - reference: PMID:17298912
    supports: SUPPORT
    snippet: Hepatitis B vaccines have been licensed since 1982... Long-term protection
      has been demonstrated.
    explanation: The article discusses the long-term protection conferred by hepatitis
      B vaccines, supporting their role in preventing HBV infection.
  - reference: PMID:22643598
    supports: SUPPORT
    snippet: Hepatitis B is a preventable disease; a safe and effective vaccine has
      been available for 30 years.
    explanation: The article states that hepatitis B is preventable through vaccination,
      supporting the statement.
  - reference: PMID:19187625
    supports: SUPPORT
    snippet: The chronic HBV carrier rate in children &lt; 10 years of age decreased
      from 10.0% before the mass vaccination to 1.0% - 2.0% in 2006.
    explanation: The article provides evidence from China&#39;s mass vaccination program,
      showing a significant reduction in HBV carrier rates due to vaccination.
  treatment_term:
    preferred_term: vaccination
    term:
      id: MAXO:0001017
      label: vaccination
review_notes: Enhanced pathophysiology section based on 2024 research including NTCP
  receptor mechanism, cccDNA formation, HBx protein function, DNA integration pathways,
  immune evasion mechanisms (TLR, cGAS-STING dampening), and T cell exhaustion with
  checkpoint receptor upregulation. Added GO biological process terms for viral entry,
  DNA integration, epigenetic regulation, and immune checkpoint pathways. Expanded
  cell type annotations including Kupffer cells and regulatory T cells. Added locations
  field consistently using UBERON terms as per schema requirements.
disease_term:
  preferred_term: hepatitis B virus infection
  term:
    id: MONDO:0005344
    label: hepatitis B virus infection
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Hepatitis_B.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
</body>
</html>